Chapter 9 Previous line

Previous line identifier is [pl]

9.1 Definition

Instrument previous line refers to any anticancer treatment received, either for a prior cancer or for the current cancer, before the current line.

The current line is the most recently administered one that contains immune checkpoint inhibitors. It can be ongoing at the time of index cardiotoxicity, or may have been interrupted.

Non-ICI anticancer treatments are grouped by pharmacological class and all are attributed a 4-character abbreviation (e.g. cl_anth_ambi refers to a current line use of anthracycline ambirubicin). For drugs out of the list, there is an “other” section, with abbreviation othr, followed by a freetext variable.

9.2 Abbreviations

Abbreviation(s) Feature
Immune checkpoint inhibitors









Standardized 4-character abbreviations of immune checkpoint inhibitors

Atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, ipilimumab, pembrolizumab, tremelimumab




When drug name is not know, standardized abbreviations related to ICI class.

Anti-PD1, anti-PD-L1, anti-CTLA4

Also pd1_other, pdl1_other, and ctla4_other to refer to an ICI from a class that is not in the aforementioned list (e.g. a new anti-PD1)

Other anticancer treatments
anth Anthracyclines
alky Alkylating agents
anme Antimetabolites
plal Plant Alkaloïds
atbo Antitumor antibiotics
topo Topoisomerase inhibitors
her2 Anti-HER2 therapies
vegf Vascular Endothelial Growth Factor inhibitors
bcra BCR-ABL inhibitors
btki Bruton Tyrosin Kinase inhibitors
rafm RAF or MEK inhibitors
egfr Endothelial Growth Factor Receptor inhibitors
prot Proteasom inhibitors
cell Cell Therapies (mostly CAR-T Cells)
immd Immunomodulators, other than Immune Checkpoint Inhibitors and Cell Therapies